关键词：急性痛风药物行业政策、急性痛风药物行业产业链、急性痛风药物市场规模、急性痛风药物市 场竞争格局、急性痛风药物重点企业介绍、急性痛风药物行业发展趋势 一、急性痛风药物行业定义及分类 内容概要：急性痛风是指痛风性关节炎急性发作。作为一种因嘌呤代谢紊乱和（或）尿酸排泄减少所引 发的疾病，急性痛风在全球范围内的发病率呈上升趋势，并呈年轻化发展趋势。18～35岁的年轻高尿酸 血症及痛风患者占比近60%，且男性比例显超女性。2024年，全球全球急性痛风患病人数增长至4540万 例，其中，中国急性痛风患病人数1940万例；预计2025年，全球全球急性痛风患病人数将增长至4770万 例，其中，中国急性痛风患病人数约2220万例。抗痛风急性发作期药物在缓解痛风急性发作症状方面发 挥着关键作用。虽近几年发病人数增加，但因价格上涨，销售量下降，近几年全球急性痛风药物市场规 模整体较稳定。预计2025年，全球急性痛风药物市场规模约为1.5美元，中国急性痛风药物市场规模约 0.1亿美元。 上市企业：海创药业[688302]、恒瑞医药[600276]、益方生物[688382]、一品红[300723] 相关企业：成都苑东生物制药股 ...

沪深股通今日合计成交2076.35亿，其中寒武纪和中际旭创分居沪股通和深股通个股成交额首位。板块 主力资金方面，商贸零售板块主力资金净流入居首。ETF成交方面，标普消费ETF（159529）成交额环 比增长301%。 龙虎榜方面，多只商业航天概念股遭游资抛售，其中雷科防务遭一家实力游资（国泰海通证券上海新闸 路）卖出1.69亿，航天科技遭一家实力游资（招商证券深圳深南大道）卖出0.65亿，中超控股遭三家实 力游资（国泰海通证券成都北一环路、中泰证券湖北分公司、国泰海通证券南京太平南路）合计卖出 1.65亿。永辉超市今日涨停，获两家一线游资席位（中国银河证券大连黄河路、国泰海通证券上海新闸 路）分别买入3.95亿、1.5亿，同时获沪股通买入2.16亿。 一、沪深股通前十大成交 今日沪股通总成交金额为961.19亿，深股通总成交金额为1115.17亿。 | | | 沪股通( 12月16日 ) | | | --- | --- | --- | --- | | 排名 | 股票代码 | 股票名称 | 成交金额(亿元) | | 1 | 688256 | 寒武纪 | 18.26 | | 2 | 600519 | 贵州茅台 | ...

香港联交所最新资料显示，12月9日，小摩增持恒瑞医药（01276）387.9413万股，每股作价72.5974港 元，总金额约为2.82亿港元。增持后最新持股数目约为2141.30万股，最新持股比例为8.29%。 责任编辑：卢昱君 香港联交所最新资料显示，12月9日，小摩增持恒瑞医药（01276）387.9413万股，每股作价72.5974港 元，总金额约为2.82亿港元。增持后最新持股数目约为2141.30万股，最新持股比例为8.29%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

香港联交所最新资料显示，12月9日，小摩增持恒瑞医药（600276）(01276)387.9413万股，每股作价 72.5974港元，总金额约为2.82亿港元。增持后最新持股数目约为2141.30万股，最新持股比例为8.29%。 ...

Core Insights - The FZOCUS-1 study has been published in the prestigious journal "CA: A Cancer Journal for Clinicians," marking a significant milestone for clinical oncology research in China [1][2] - This study is the first clinical research in the field of gynecological oncology conducted by Chinese researchers to be featured in this top-tier journal [1] Study Overview - FZOCUS-1 is a randomized, double-blind, placebo-controlled Phase III clinical trial conducted over six years across 54 centers in China, involving 674 patients [1] - The study evaluates the efficacy and safety of the first domestically developed PARP inhibitor, Furazlopar, either alone or in combination with the anti-angiogenic drug Apatinib, for first-line maintenance treatment of advanced ovarian cancer [1] Key Findings - Patients receiving Furazlopar monotherapy achieved a median progression-free survival (PFS) of 29.9 months, showing a statistically significant difference compared to the placebo group [1] - In the subgroup of patients with BRCA mutations, the median PFS increased dramatically from 16.6 months in the placebo group to 47.8 months with Furazlopar monotherapy, significantly reducing the risk of disease progression or death [1] - The study confirmed that the use of PARP inhibitors alone can achieve ideal efficacy in HRD-positive populations, avoiding the side effects and economic burden associated with combination therapies [1] Industry Impact - The successful publication of the FZOCUS-1 study is seen as a vital contribution of "Chinese data" and "Chinese wisdom" to global ovarian cancer treatment practices [2] - The results reflect the commitment of the company, Heng Rui Medicine, to innovation and addressing global clinical challenges through independent research and development [2] - Furazlopar has been included in the medical insurance catalog, significantly improving drug accessibility for Chinese ovarian cancer patients [2]

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].

来源：环球网 12月14日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》（《CA: A Cancer Journal for Clinicians》）（影响因子高232.4），新闻发布会在北京举行。作为《CA》首次刊载由中国研究者开展 的妇科肿瘤领域临床研究，FZOCUS-1研究不仅印证了我国自主创新药临床研究已进入国际引领阶段， 更是"中国方案"在全球卵巢癌治疗领域中贡献中国智慧的重要体现。 办方供图） 更为复杂的是，卵巢癌具有高度异质性，不同患者对治疗的反应差异显著。如何在标准治疗后有效延长 患者的无进展生存期、推迟复发时间、最终改善总生存期，同时尽可能减少治疗副作用、提高生活质 量，成为全球妇科肿瘤专家共同攻坚的核心方向。近年来，PARP抑制剂等靶向药物的出现为治疗带来 了新曙光，但"哪些患者最适合何种治疗方案"这一精准医学的核心问题，仍需大规模、高质量的前瞻性 临床研究予以解答。 FZOCUS-1研究正是为回答上述全球性难题而设计的一项重要临床研究。该研究是一项在全国54家中心 开展、历时六年的随机双盲安慰剂对照Ⅲ期临床试验，共纳入674例患者，旨在评估恒瑞医药自主研发 的全国首个P ...

Core Viewpoint - The Shanghai Stock Exchange 180 Index shows a slight increase, with notable gains in key constituent stocks, reflecting a stable market environment amid industrial growth and potential policy changes [1][2]. Group 1: Market Performance - As of December 15, 2025, the Shanghai 180 Index rose by 0.13%, with significant increases in stocks such as China Merchants Energy (up 4.77%) and Ping An Insurance (up 4.62%) [1]. - The Shanghai 180 ETF Index Fund increased by 0.17%, with the latest price reported at 1.2 yuan [1]. Group 2: Industrial Growth - In November, the industrial added value for large-scale enterprises increased by 4.8% year-on-year, driven by advancements in the equipment manufacturing sector [1]. - The equipment manufacturing industry saw a robust growth of 7.7% in added value year-on-year, contributing 56.4% to the overall industrial growth [1]. Group 3: Investment Insights - According to AVIC Securities, the market may remain stable towards the end of the year, with a focus on the impact of potential interest rate hikes by the Bank of Japan on global liquidity [1]. - Recommendations include a balanced allocation between dividend and technology styles, with attention to industries that may experience marginal catalysts, anticipating a "spring rally" [1]. Group 4: ETF Composition - The Shanghai 180 Index consists of 180 securities selected for their large market capitalization and liquidity, reflecting the overall performance of core listed companies in the Shanghai market [2]. - As of November 28, 2025, the top ten weighted stocks in the Shanghai 180 Index account for 26.13% of the index, including major companies like Kweichow Moutai and Ping An Insurance [2].

Group 1 - The global anticoagulant market exceeds $20 billion, with existing anticoagulants posing additional bleeding risks while preventing thrombosis. There is room for improvement in both efficacy and safety of these drugs [1] - FXI/FXIa inhibitors are expected to become safer alternatives to current anticoagulants, as they specifically target the intrinsic coagulation pathway, potentially reducing bleeding risks while maintaining anticoagulant efficacy [1] - No FXI/FXIa inhibitors have been approved yet, but several candidates, including Novartis' abelacimab, Bayer's asundexian, and BMS/Johnson & Johnson's milvexian, are in registration clinical trials [1] Group 2 - Bayer's asundexian has shown superior efficacy in phase 3 clinical trials for secondary stroke prevention, marking it as the first FXI/FXIa inhibitor to meet key clinical endpoints [1] - FXI/FXIa inhibitors demonstrate significant safety advantages over DOACs, particularly in patients at high risk of bleeding, and are expected to challenge standard treatments in various indications [1] - FXI small nucleic acid drugs, still in early development, show promising early pharmacokinetic and pharmacodynamic data, with potential for improved patient compliance due to less frequent dosing [2]

国信证券主要观点如下： 国信证券发布研报称，全球抗凝药市场规模超200亿美元，现有的抗凝药物在预防血栓的同时，会带来 额外的出血风险;抗凝血药物的有效性(抗血栓能力)和安全性(减少出血风险)仍有提升空间。FXI/FXIa有 望成为现有抗凝血药物的升级和补充，具备百亿美金以上的潜在市场空间。建议关注恒瑞医药 （600276）(600276.SH，01276)：FXI单抗SHR-2004进入3期临床，在国产分子中领先;并关注拥有FXI小 核酸药物管线的公司。 风险提示：临床结果不及预期的风险、临床进度不及预期的风险、海外开发不及预期的风险、商业化不 及预期的风险。 近期，拜耳的asundexian在卒中二级预防的3期临床中取得优效，成为首个达到关键临床主要临床终点的 FXI/FXIa抑制剂。此前，asundexian在房颤患者的卒中预防的3期临床中未达到有效性终点，milvexian在 ACS患者中相比安慰剂同样未达到优效。根据现有临床数据，FXI/FXIa抑制剂相比于DOACs体现出显 著的安全性优势，可能在高出血风险的患者中占据竞争优势。另一方面，在内源性凝血通路的作用占主 导地位的适应症中，FXI/FXIa ...